Table 6.
Living donor follow-up
| Survey question | Overall | Stratified by state COVID-19 cumulative incidence |
||
|---|---|---|---|---|
| Low | Moderate | High | ||
| Have you continued living donor follow-up during the pandemic? (n = 117) | % (n) | % (n) | % (n) | % (n) |
| Yes: clinical and labs | 52 (61) | 59 (22) | 42 (16) | 55 (23) |
| Yes: clinical only, but labs deferred | 20 (23) | 14 (5) | 24 (9) | 21 (9) |
| No (we have paused follow-up) | 28 (33) | 27 (10) | 34 (13) | 24 (10) |
| If you have continued clinical living donor follow-up what modalities do you use for patient interactions? Select all that apply. (n = 90) | % (n) | % (n) | % (n) | % (n) |
| Assessment in clinic | 21 (19) | 17 (5) | 19 (5) | 26 (9) |
| Telehealth: telephone-based | 66 (59) | 59 (17) | 74 (20) | 65 (22) |
| Telehealth: video-based | 73 (66) | 69 (20) | 81 (22) | 71 (24) |
| If you continued living donor follow-up lab testing during the pandemic, where are labs performed? Select all that apply. (n = 74) | % (n) | % (n) | % (n) | % (n) |
| Transplant hospital | 61 (45) | 61 (17) | 71 (15) | 52 (13) |
| Community lab | 80 (59) | 89 (25) | 67 (14) | 80 (20) |
| Home-based phlebotomy service | 19 (14) | 18 (5) | 14 (3) | 24 (6) |
| Has your center used telehealth for living donor follow-up prior to the COVID-19 pandemic? (n = 116) | % (n) | % (n) | % (n) | % (n) |
| Yes | 17 (20) | 19 (7) | 13 (5) | 19 (8) |
| No | 83 (96) | 81 (29) | 87 (33) | 81 (34) |
| Do you plan to use telehealth for living donor care after the COVID-19 pandemic? (n = 115) | % (n) | % (n) | % (n) | % (n) |
| Yes, at higher than pre-pandemic utilization | 61 (70) | 68 (25) | 54 (20) | 61 (25) |
| Yes, selectively | 33 (38) | 24 (9) | 38 (14) | 37 (15) |
| No | 6 (7) | 8 (3) | 8 (3) | 2 (1) |
COVID-19, coronavirus disease 2019; lab, laboratory; labs, laboratory tests.